Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
A Phase 1/2a, Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
Sponsor: Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Terminated
Study terminated early due to business decision.
Other Chronic Lymphocytic Leukemia trials with similar outcome
A PHASE1/PHASE2 clinical study on Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Hangzhou Zenshine Pharmaceuticals Co., Ltd. and has accumulated 10 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Feb 2022 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hangzhou Zenshine Pharmaceuticals Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .